Back

Current challenges in risk stratification of cancer therapy-related cardiovascular toxicity

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Emerging insights in cardio-oncology: biomarkers, cardiotoxicity, and protective therapies Cardio-Oncology HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Isabel Martins Moreira

Hospital Center of Tras-os-Montes and Alto Douro, Vila Real (Portugal)

6 More presentations in this session

Presentation thumbnail
Sacubitril-valsartan reduced H-FABP, hs-cTnT, hs-CRP and monocyte-to-lymphocyte ratio in anthracycline-treated preclinical models through NLRP3-mTOR-AKT pathways
Doctor N. Maurea (Naples, IT)
Abstract Slides Video
Presentation thumbnail
Heart failure hospitalization and outcomes in cancer patients undergoing immune checkpoint inhibitor treatment: a systematic review and meta-analysis
Doctor N. Sari (Jakarta, ID)
Abstract Slides Video
Presentation thumbnail
The predictive value of baseline troponin measurements in patients treated with immune checkpoint inhibitors
Doctor M. Laufer-Perl (Tel Aviv, IL)
Abstract Slides Video
Presentation thumbnail
GLP1-RA associated with SGLT2i as new therapy of anthracycline-induced cardiotoxicity under hyperglycemia: biochemical and preclinical evidences
Doctor N. Maurea (Naples, IT)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in cancer patients with diabetes mellitus
Doctor M. Gvili Perelman (Tel Aviv, IL)
Abstract Slides Video

Access the full session

Session thumbnail
Emerging insights in cardio-oncology: biomarkers, cardiotoxicity, and protective therapies
Video

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Cancer therapy-related cardiovascular toxicity: what is the accuracy of baseline cardiovascular risk stratification in the prediction of its occurrence?
thumbnail
Congress Presentation
A study to assess the ability of the HFA-ICOS risk stratification tool to predict cancer therapy-related cardiac dysfunction for patients receiving anthracycline chemotherapy.
thumbnail
Congress Presentation
Validation of the HFA-ICOS risk assessment tool with real-world data from a prospective cohort of breast cancer patients in treatment with anthracyclines and trastuzumab

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources